Swedish Orphan Biovitrum is registered under the ticker STO:SOBI . Swedish Orphan Biovitrum has acquired 3 organizations. Their most recent acquisition was Dova Pharmaceuticals on Sep 30, 2019. They acquired Dova Pharmaceuticals for $915M.

Swedish Orphan Biovitrum AB (publ) (Sobi™) (http://www.sobi.com/) har utsett Paula Treutiger till ny Head of Communications and Investor Relations, med ansvar för

& STOCKHOLM--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced that the European Medicines Agency’s (EMA) Pediatric Committee (PDCO) has adopted an opinion agreeing to the pediatric investigational plan for the companies’ long-lasting, fully-recombinant Factor IX Fc fusion protein (rFIXFc). Jörgen Winroth is Vice President, Head of Investor Relations at Swedish Orphan Biovitrum AB. View Jörgen Winroth’s professional profile on Relationship Science, the database of decision makers. Paula Treutiger, Head of Communication & Investor Relations + 46 733 666 599 paula.treutiger@sobi.com. Linda Holmström, Corporate Communication & Investor Relations + 46 708 734 095 linda.holmstrom@sobi.com. Swedish Orphan Biovitrum AB (publ) Postal address SE-112 76 Stockholm, Sweden Phone: 46 8 697 20 00 www.sobi.com 2021-04-13 · Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced that the first patient has been dosed in the phase 3, open-label, interventional XTEND-Kids study of efanesoctocog alfa (BIVV001) in paediatric subjects with severe haemophilia A. Get the latest Swedish Orphan Biovitrum AB (SOBI.

Swedish orphan biovitrum investor relations

Paula Treutiger, Head of Communication & Investor Relations linda.holmstrom@sobi.com jorgen.winroth@sobi.com. Paula Treutiger, Head of. Communications & Investor Relations +46 733 666 599 paula.treutiger@sobi. This website has been developed by Swedish Orphan Biovitrum AB (publ) (hereinafter referred to as "Sobi"). Sobi offers this website, including the information Swedish Orphan Biovitrum AB (publ) (Sobi™) has released the company's Paula Treutiger, Head of Communication & Investor Relations Hon kommer närmast från Sobi, Swedish Orphan Biovitrum (publ), där hon var Senior Corporate Communications and Investor Relations Manager. Linda får Oncopeptides rekryterar Linda Holmström till ny chef för Investor Relations.

Swedish Orphan Biovitrum, även kända under namnet Sobi, är ett internationellt läkemedelsbolag. Störst inriktning återfinns inom tillhandahållandet av innovativa behandlingar och service för patienter med sällsynta sjukdomar. Produkterna fokuserar på inflammationssjukdomar och genetiska sjukdomar.

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) Find out more Head of Communications & Investor relations. paula.treutiger@sobi.com +46 73 Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sweden.

Swedish Orphan Biovitrum AB (publ) (Sobi) tillkännagav idag att företaget beslutat att tillfälligt dra Jörgen Winroth, Vice President, Head of Investor Relations.

Investment Manager Investor AB. Education: B.Sc. (Business and Econ) Independence: Namnändring från Biovitrum AB till Swedish Orphan Biovitrum AB 24 juni. 2006. Ny notering på O-listan 15 september, introduktionskurs 100 kr. Emissioner m.m.

Swedish orphan biovitrum investor relations

Paula will join Sobi on 1 January 2019 and be part of Sobi’s Executive Committee. Paula joins Sobi from Medicover, an international healthcare and diagnostic services provider listed on Nasdaq Stockholm, where she Investor will report Swedish Orphan Biovitrum as an Operating Investment, valued at the official stock price. For more information about the proposed merger; www.biovitrum.com 1) This will require Jörgen Winroth is Vice President, Head of Investor Relations at Swedish Orphan Biovitrum AB. View Jörgen Winroth’s professional profile on Relationship Science, the database of decision makers.
Nordea finans blanketter

Investors At Sobi, we are transforming the lives of people affected by rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) Find out more Head of Communications & Investor relations.

2010-05-18 Investor Capital STOCKHOLM, Sept. 30, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by Swedish Orphan Biovitrum AB: Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH. Publicerad: 2020-12-10 (Cision) Swedish Orphan Biovitrum AB: Sobi och Apellis redovisar positiva topline-resultat från fas 3-studien PEGASUS efter 48 veckors behandling med pegcetacoplan vid PNH Here we present financial data and our latest reports to help you understand how we are doing. You’ll also find links to more detailed investor information, in English and Swedish. Swedish Orphan Biovitrum General Information Description.
Semester europa 2021 corona

Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ) Investor Relations 0733 666 599 paula.treutiger@sobi.com Linda

Sobi - Swedish Orphan Biovitrum AB (publ)Stockholm Senior Manager Corporate Communication and Investor Relations. Sobi - Swedish Orphan Biovitrum AB (publ). aug 2016 – dec 2020 4 år 5 månader.